Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.

Photocure ASA, a company specializing in bladder cancer treatment, recently shared a report comparing the healthcare resource usage and expenses linked to blue light versus white light cystoscopy in non-muscle-invasive bladder cancer cases. The study, titled 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer,' was released on August 11, 2026. This research sheds light on the financial implications of these two procedures in treating the mentioned type of bladder cancer. The company's stock is listed on the Oslo Stock Exchange under the symbol PHO.